CIBC Asset Management
BNGO icon

CIBC Asset Management’s Bionano Genomics BNGO Stock Holding History

CIBC Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20
Closed -$22K – 1089
2022
Q3 		$22K Hold
20
– – ﹤0.01% 1236
2022
Q2 		$16K Sell
20
-1
-5% -$1.03K ﹤0.01% 1260
2022
Q1 		$33K Hold
21
– – ﹤0.01% 1509
2021
Q4 		$38K Buy
21
+2
+11% +$5.35K ﹤0.01% 1530
2021
Q3 		$63K Buy
+19
New +$66.5K ﹤0.01% 1445

Other funds holding BNGO

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIBC Asset Management's BNGO Position: Q4 2022 in Review

CIBC Asset Management sold out of Bionano Genomics (BNGO) in Q4 2022, closing a stake of 20 shares — an estimated $22K sold.

CIBC Asset Management first reported a position in BNGO in Q3 2021 and held it in 5 quarters. The position peaked at $63K in Q3 2021. 143 funds tracked by Wall St. Rank hold BNGO as of Q4 2022.

  • CIBC Asset Management reported no remaining Bionano Genomics position as of Q4 2022 after selling out during the quarter.
  • CIBC Asset Management sold 20 Bionano Genomics shares in Q4 2022, an estimated $22K.
  • CIBC Asset Management first reported a position in Bionano Genomics in Q3 2021 and held it in 5 quarters.
  • CIBC Asset Management's Bionano Genomics position peaked at $63K in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2022.

Based on CIBC Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.